BMRN
BioMarin Pharmaceutical Inc. NASDAQ Listed Jul 26, 1999$54.69
-0.60%
vs $55.02
Mkt Cap $10.8B
52w Low $49.67
34.8% of range
52w High $64.08
50d MA $54.26
200d MA $55.66
P/E (TTM)
30.4x
EV/EBITDA
17.2x
P/B
1.7x
Debt/Equity
0.1x
ROE
5.7%
P/FCF
14.9x
RSI (14)
40.00
ATR (14)
$1.56
Beta
0.29
50d MA
$54.26
200d MA
$55.66
Avg Volume
2.3M
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
770 Lindaro Street · San Rafael, CA 94901 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 4, 2026 | AMC | 0.94 | 0.54 | -42.6% | 55.46 | +0.2% | -4.0% | +2.6% | -0.9% | -0.1% | -2.7% | — |
| Feb 23, 2026 | AMC | 0.17 | -0.24 | -241.7% | 62.92 | -4.2% | -0.5% | -1.9% | -0.5% | +1.0% | -3.2% | — |
| Oct 27, 2025 | AMC | -0.15 | 0.12 | +180.0% | 52.67 | +1.4% | +1.6% | -3.0% | +0.1% | +3.2% | -1.3% | — |
| Aug 4, 2025 | AMC | 0.86 | 1.44 | +67.2% | 60.31 | +5.0% | +2.7% | -2.0% | -2.0% | -3.6% | -0.9% | — |
| May 1, 2025 | AMC | 0.94 | 1.13 | +20.2% | 62.71 | +2.5% | -1.1% | +0.0% | -3.9% | -0.5% | +0.8% | — |
| Feb 19, 2025 | AMC | 0.54 | 0.92 | +70.4% | 65.61 | +6.7% | +4.8% | -0.7% | +1.1% | +3.1% | -3.3% | — |
| Oct 29, 2024 | AMC | 0.78 | 0.91 | +16.7% | 69.91 | -0.3% | -4.6% | -1.2% | +1.1% | -0.9% | +0.0% | — |
| Aug 5, 2024 | AMC | 0.36 | 0.96 | +168.3% | 80.47 | +9.1% | +8.0% | -0.7% | +1.9% | +0.8% | +0.4% | — |
| Apr 24, 2024 | AMC | 0.31 | 0.71 | +127.7% | 91.20 | -5.4% | -9.9% | -1.5% | +1.5% | -1.7% | +3.2% | — |
| Feb 22, 2024 | AMC | 0.44 | 0.49 | +11.4% | 89.97 | +1.1% | +1.4% | -1.2% | +0.6% | -2.5% | -2.4% | — |
| Nov 1, 2023 | AMC | 0.46 | 0.46 | +0.0% | 84.01 | -3.6% | -5.2% | -0.1% | -4.2% | +12.2% | +0.0% | — |
| Jul 31, 2023 | AMC | 0.47 | 0.54 | +14.9% | 87.93 | -1.1% | +1.2% | -0.7% | -0.7% | +0.9% | -0.8% | — |
| Apr 26, 2023 | AMC | 0.43 | 0.60 | +39.5% | 93.00 | -1.0% | -0.6% | +3.9% | +1.0% | -3.3% | -0.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 19 | Citigroup | Initiates | Buy | $75 | $49.67 | $50.25 | +1.2% | +0.3% | +0.8% | +7.8% | -0.0% | -2.2% |
| May 11 | Goldman | Reiterates | Neutral | $69 | $54.06 | $53.46 | -1.1% | -2.7% | +0.6% | +1.3% | -0.6% | -2.7% |
| Apr 27 | Morgan Stanley | Reiterates | Overweight | $120 | $53.18 | $53.69 | +1.0% | +1.2% | -0.9% | +1.7% | -0.6% | +0.3% |
| Mar 11 | BofA Securities | Maintains | Buy → Buy | — | $60.89 | $60.18 | -1.2% | -0.9% | -2.1% | -0.9% | -1.8% | -2.4% |
| Mar 4 | Barclays | Maintains | Overweight → Overweight | — | $58.53 | $59.00 | +0.8% | +3.2% | +0.2% | +0.9% | -0.4% | +0.0% |
| Mar 2 | Freedom Broker | Maintains | Buy → Buy | — | $61.73 | $60.71 | -1.7% | -3.2% | -2.0% | +3.2% | +0.2% | +0.9% |
| Mar 2 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $61.73 | $60.71 | -1.7% | -3.2% | -2.0% | +3.2% | +0.2% | +0.9% |
| Feb 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $61.44 | $61.36 | -0.1% | -0.5% | +1.0% | -3.2% | -2.0% | +3.2% |
| Feb 25 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $62.62 | $62.14 | -0.8% | -1.9% | -0.5% | +1.0% | -3.2% | -2.0% |
| Feb 25 | Bernstein | Maintains | Outperform → Outperform | — | $62.62 | $62.14 | -0.8% | -1.9% | -0.5% | +1.0% | -3.2% | -2.0% |
| Feb 25 | Guggenheim | Maintains | Buy → Buy | — | $62.62 | $62.14 | -0.8% | -1.9% | -0.5% | +1.0% | -3.2% | -2.0% |
| Feb 24 | Oppenheimer | Maintains | Outperform → Outperform | — | $62.92 | $60.30 | -4.2% | -0.5% | -1.9% | -0.5% | +1.0% | -3.2% |
| Feb 18 | Wells Fargo | Maintains | Overweight → Overweight | — | $59.95 | $60.08 | +0.2% | +3.1% | +2.6% | +1.0% | -1.8% | -0.5% |
| Feb 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $57.15 | $57.26 | +0.2% | +1.7% | -0.6% | +3.2% | +1.1% | -0.6% |
| Jan 20 | Canaccord Genuity | Upgrade | Hold → Buy | — | $54.59 | $54.73 | +0.3% | +3.2% | +0.8% | +0.7% | -1.7% | +1.0% |
| Dec 23 | Truist | Maintains | Buy → Buy | — | $59.28 | $59.59 | +0.5% | +3.1% | -1.6% | -0.3% | +0.2% | -1.7% |
| Dec 22 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $61.15 | $60.59 | -0.9% | -3.1% | +3.1% | -1.6% | -0.3% | +0.2% |
| Dec 3 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $53.89 | $53.52 | -0.7% | +0.8% | -0.9% | -0.8% | -0.2% | +0.8% |
| Nov 6 | Stifel | Downgrade | Buy → Hold | — | $52.80 | $52.03 | -1.5% | -1.8% | -0.7% | +2.4% | +4.3% | +0.7% |
| Nov 3 | Freedom Broker | Maintains | Buy → Buy | — | $53.57 | $53.03 | -1.0% | -1.3% | -0.6% | +0.5% | -1.8% | -0.7% |
| Nov 3 | Bernstein | Maintains | Outperform → Outperform | — | $53.57 | $53.03 | -1.0% | -1.3% | -0.6% | +0.5% | -1.8% | -0.7% |
| Oct 28 | Morgan Stanley | Maintains | Overweight → Overweight | — | $52.67 | $53.40 | +1.4% | +1.6% | -3.0% | +0.1% | +3.2% | -1.3% |
| Oct 28 | Truist | Maintains | Buy → Buy | — | $52.67 | $53.40 | +1.4% | +1.6% | -3.0% | +0.1% | +3.2% | -1.3% |
| Oct 28 | Barclays | Maintains | Overweight → Overweight | — | $52.67 | $53.40 | +1.4% | +1.6% | -3.0% | +0.1% | +3.2% | -1.3% |
| Oct 28 | Stifel | Maintains | Buy → Buy | — | $52.67 | $53.40 | +1.4% | +1.6% | -3.0% | +0.1% | +3.2% | -1.3% |
| Oct 28 | Wells Fargo | Maintains | Overweight → Overweight | — | $52.67 | $53.40 | +1.4% | +1.6% | -3.0% | +0.1% | +3.2% | -1.3% |
| Oct 27 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $54.48 | $54.98 | +0.9% | -3.3% | +1.6% | -3.0% | +0.1% | +3.2% |
| Oct 9 | JP Morgan | Maintains | Overweight → Overweight | — | $54.69 | $55.39 | +1.3% | -1.5% | -2.8% | +0.2% | +0.0% | +1.2% |
| Aug 6 | Guggenheim | Maintains | Buy → Buy | — | $61.93 | $61.58 | -0.6% | -2.0% | -2.0% | -3.6% | -0.9% | +0.1% |
| Aug 5 | UBS | Maintains | Buy → Buy | — | $60.31 | $63.34 | +5.0% | +2.7% | -2.0% | -2.0% | -3.6% | -0.9% |
| Jul 22 | Morgan Stanley | Maintains | Overweight → Overweight | — | $56.56 | $56.81 | +0.4% | +4.7% | +0.8% | +0.2% | -1.3% | -1.5% |
| Jul 14 | JP Morgan | Maintains | Overweight → Overweight | — | $58.10 | $58.06 | -0.1% | +0.2% | -2.8% | +3.1% | -0.0% | -1.9% |
| May 5 | Goldman Sachs | Maintains | Buy → Buy | — | $62.03 | $61.83 | -0.3% | +0.0% | -3.9% | -0.5% | +0.8% | -1.6% |
| May 2 | Citigroup | Maintains | Neutral → Neutral | — | $62.71 | $64.26 | +2.5% | -1.1% | +0.0% | -3.9% | -0.5% | +0.8% |
| Feb 24 | Oppenheimer | Upgrade | Perform → Outperform | — | $68.25 | $68.38 | +0.2% | +1.1% | +3.1% | -3.3% | +0.5% | +3.0% |
| Feb 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $65.61 | $70.00 | +6.7% | +4.8% | -0.7% | +1.1% | +3.1% | -3.3% |
| Feb 20 | UBS | Maintains | Buy → Buy | — | $65.61 | $70.00 | +6.7% | +4.8% | -0.7% | +1.1% | +3.1% | -3.3% |
| Feb 20 | BofA Securities | Maintains | Buy → Buy | — | $65.61 | $70.00 | +6.7% | +4.8% | -0.7% | +1.1% | +3.1% | -3.3% |
| Feb 20 | Scotiabank | Maintains | Sector Perform → Sector Perform | — | $65.61 | $70.00 | +6.7% | +4.8% | -0.7% | +1.1% | +3.1% | -3.3% |
| Feb 20 | Citigroup | Maintains | Neutral → Neutral | — | $65.61 | $70.00 | +6.7% | +4.8% | -0.7% | +1.1% | +3.1% | -3.3% |
| Feb 20 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $65.61 | $70.00 | +6.7% | +4.8% | -0.7% | +1.1% | +3.1% | -3.3% |
| Feb 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $65.61 | $70.00 | +6.7% | +4.8% | -0.7% | +1.1% | +3.1% | -3.3% |
| Dec 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $65.97 | $65.45 | -0.8% | +0.4% | -0.4% | -0.7% | +2.5% | -3.7% |
| Oct 30 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $69.91 | $69.67 | -0.3% | -4.6% | -1.2% | +1.1% | -0.9% | +0.0% |
| Oct 30 | UBS | Maintains | Buy → Buy | — | $69.91 | $69.67 | -0.3% | -4.6% | -1.2% | +1.1% | -0.9% | +0.0% |
| Oct 30 | Canaccord Genuity | Maintains | Hold → Hold | — | $69.91 | $69.67 | -0.3% | -4.6% | -1.2% | +1.1% | -0.9% | +0.0% |
| Oct 30 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $69.91 | $69.67 | -0.3% | -4.6% | -1.2% | +1.1% | -0.9% | +0.0% |
| Oct 30 | Evercore ISI | Maintains | Outperform → Outperform | — | $69.91 | $69.67 | -0.3% | -4.6% | -1.2% | +1.1% | -0.9% | +0.0% |
| Oct 30 | Baird | Maintains | Neutral → Neutral | — | $69.91 | $69.67 | -0.3% | -4.6% | -1.2% | +1.1% | -0.9% | +0.0% |
| Oct 30 | JP Morgan | Maintains | Overweight → Overweight | — | $69.91 | $69.67 | -0.3% | -4.6% | -1.2% | +1.1% | -0.9% | +0.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | Friberg Gregory ROff | EVP, Chief R&D Officer | Sell | 3,281 | $53.85 | $177K | 51,818 | +0.57% | -4.13% |
8-K · 5.02
!!! Very High
BioMarin Pharmaceutical Inc. -- 8-K 5.02: Executive Change
Jun 4
8-K · 2.02
!! High
BioMarin Pharmaceutical Inc. -- 8-K 2.02: Earnings Results
BioMarin Pharmaceutical reported Q1 2026 earnings results on May 4, 2026, with the detailed financial performance and guidance available in the attached press release for investor evaluation.
May 4
8-K · 2.01
!!! Very High
BioMarin Pharmaceuticals Inc -- 8-K 2.01: Acquisition Completed
BioMarin Pharmaceuticals completed its acquisition of Folding@Home, expanding its portfolio and potentially enhancing drug discovery capabilities through distributed computing technology.
Apr 27
8-K
BioMarin Pharmaceuticals Inc -- 8-K Filing
BioMarin Pharmaceuticals disclosed forward-looking statements regarding future events with material risks that could cause actual results to differ significantly from current expectations.
Apr 23
8-K
Amicus Therapeutics, Inc -- 8-K Filing
Amicus Therapeutics issued forward-looking statements regarding future events and expectations, indicating the company plans strategic initiatives subject to significant risks and uncertainties.
Apr 23
8-K
Unknown — 8-K Filing
BioMarin discontinued VOXZOGO enrollment in three indications due to likely safety or efficacy concerns, narrowing the drug's market opportunity and reducing revenue potential for this pipeline asset.
Mar 16
8-K
BioMarin Pharmaceuticals Inc -- 8-K Filing
I cannot provide a meaningful analysis as the summary provided does not contain substantive information about a specific transaction, announcement, or material event affecting BioMarin Pharmaceuticals.
Feb 23
8-K · 1.01
! Medium
BioMarin Pharmaceuticals Inc -- 8-K 1.01: Financing / Debt Agreement
BioMarin completed an $850 million private placement of 5.500% senior notes due 2026, securing debt financing from qualified institutional buyers to fund operations and strategic initiatives.
Feb 12
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Dodge & Cox | 14,561,759 | $823M | — | Mar 2026 |
| 2 | Primecap Management Co/ca/ | 14,194,005 | $802M | Reduced | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 8,643,164 | $488M | New | Mar 2026 |
| 4 | Vanguard Portfolio Management Llc | 8,298,475 | $469M | New | Mar 2026 |
| 5 | Aqr Capital Management Llc | 7,676,541 | $429M | Added | Mar 2026 |
| 6 | Viking Global Investors | 7,062,077 | $399M | Added | Mar 2026 |
| 7 | Morgan Stanley | 4,631,240 | $275M | Added | Dec 2025 |
| 8 | Citadel Advisors Llc | 4,512,634 | $255M | Added | Mar 2026 |
| 9 | Fmr Llc | 3,567,031 | $202M | Added | Mar 2026 |
| 10 | Capital Research Global Investors | 3,491,386 | $197M | Added | Mar 2026 |
| 11 | Millennium Management | 3,010,308 | $170M | Reduced | Mar 2026 |
| 12 | Assenagon Asset Management S.a. | 1,920,658 | $108M | Added | Mar 2026 |
| 13 | First Trust Advisors Lp | 1,672,491 | $94M | Added | Mar 2026 |
| 14 | Northern Trust Corp | 1,586,384 | $90M | Added | Mar 2026 |
| 15 | Ubs Group Ag | 1,496,852 | $85M | Reduced | Mar 2026 |
| 16 | Pictet Asset Management Holding Sa | 1,283,622 | $76M | Added | Dec 2025 |
| 17 | Jones Hill Capital Lp | 1,268,390 | $72M | New | Mar 2026 |
| 18 | Dnb Asset Management As | 1,221,387 | $69M | Reduced | Mar 2026 |
| 19 | Point72 Asset Management | 1,199,206 | $68M | Added | Mar 2026 |
| 20 | Bank Of New York Mellon Corp | 1,144,892 | $65M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$10.80B
Enterprise Value
$9.83B
P/E (TTM)
30.38x
Forward P/E
12.73x
PEG Ratio
-1.71x
P/B
1.72x
P/S
3.35x
P/FCF
14.89x
EV/EBITDA
17.16x
Shares Out
197.4M
Financials (TTM)
Revenue
$3.22B
Net Income
$348.9M
EBITDA
$572.9M
Free Cash Flow
$725.0M
Op Cash Flow
$828.0M
EPS Basic
$1.82
EPS Diluted
$1.80
EPS Forward
$4.29
Gross Margin
77.1%
Op Margin
16.6%
Net Margin
10.8%
Balance Sheet
Total Assets
$7.59B
Total Liab.
$1.51B
Total Equity
$6.09B
Cash
$1.56B
LT Debt
$597.2M
Book Value/Sh
$31.74
Debt/Equity
0.11x
Current Ratio
5.21
Quick Ratio
3.50
Returns & Growth
ROE
5.7%
ROA
4.6%
ROIC
5.6%
Rev Growth YoY
+12.9%
EPS Growth YoY
-19.1%
Price Returns
2W
+7.6%
1M
+6.3%
3M
-7.2%
6M
+2.4%
12M
-1.3%
Technicals
52W High
$64.08
52W Low
$49.67
50d MA
$54.26
200d MA
$55.66
RSI (14)
40.00
ATR (14)
$1.56
Beta
0.29
Avg Volume
2.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$89.64
High
$120.00
Low
$60.00
Median
$91.50
Data updated apr 24, 2026 10:15pm
· Source: financialmodelingprep.com